Loading...
XJPX2370
Market cap59mUSD
Jan 17, Last price  
35.00JPY
1D
0.00%
1Q
-14.63%
Jan 2017
-74.82%
Name

Medinet Co Ltd

Chart & Performance

D1W1MN
XJPX:2370 chart
P/E
—
P/S
12.05
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.70%
Rev. gr., 5y
-6.21%
Revenues
769m
+16.17%
2,900,215,0003,202,490,0002,674,190,0002,190,986,0002,110,453,0001,843,995,0001,674,379,0001,909,324,0001,704,004,000998,278,0001,059,021,000783,035,000683,033,000633,672,000661,543,000768,501,000
Net income
-1.28b
L-11.19%
245,873,000438,556,000-542,527,000-624,988,000-348,419,000-1,580,722,000-1,712,320,000-1,643,198,000-2,603,685,000-3,048,545,000-795,307,000-842,012,000-843,395,000-1,254,091,000-1,437,950,000-1,276,994,000
CFO
-1.27b
L+0.59%
319,602,000528,004,000-251,574,000-337,537,000-516,011,000-1,020,104,000-1,567,375,000-1,088,096,000-1,333,145,000-2,499,487,000-938,444,000-632,923,000-974,695,000-1,161,202,000-1,263,723,000-1,271,195,000

Profile

MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. Further, the company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.
URL
https://www.medinet-inc.co.jp/
IPO date
Oct 08, 2003
Employees
92
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
768,501
16.17%
661,543
4.40%
633,672
-7.23%
Cost of revenue
655,808
1,059,965
1,070,972
Unusual Expense (Income)
NOPBT
112,693
(398,422)
(437,300)
NOPBT Margin
14.66%
Operating Taxes
3,813
4,158
5,301
Tax Rate
3.38%
NOPAT
108,880
(402,580)
(442,601)
Net income
(1,276,994)
-11.19%
(1,437,950)
14.66%
(1,254,091)
48.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,462,426
1,132,307
1,590,637
BB yield
-12.39%
-10.48%
-8.19%
Debt
Debt current
781
1,526
1,992
Long-term debt
781
3,088
6,606
Deferred revenue
Other long-term liabilities
204,025
177,360
156,426
Net debt
(4,649,619)
(4,603,385)
(5,042,017)
Cash flow
Cash from operating activities
(1,271,195)
(1,263,723)
(1,161,202)
CAPEX
(53,586)
(84,777)
(40,531)
Cash from investing activities
65,143
3,267
(20,227)
Cash from financing activities
1,460,899
1,157,693
1,584,835
FCF
87,697
(358,248)
(352,828)
Balance
Cash
4,651,181
4,396,333
4,499,095
Long term investments
211,666
551,520
Excess cash
4,612,756
4,574,922
5,018,931
Stockholders' equity
3,771,217
4,298,838
4,151,333
Invested Capital
1,624,354
924,770
1,492,570
ROIC
8.54%
ROCE
2.07%
EV
Common stock shares outstanding
256,490
216,084
198,070
Price
46.00
-8.00%
50.00
-48.98%
98.00
40.00%
Market cap
11,798,551
9.20%
10,804,222
-44.34%
19,410,826
60.60%
EV
7,148,932
6,200,837
14,368,809
EBITDA
227,344
(295,252)
(331,441)
EV/EBITDA
31.45
Interest
27
5,753
98
Interest/NOPBT
0.02%